Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law enforcement and forensic researchers to analyze a broader range of evidence more quickly, accurately and reliably // Collaboration strengthens QIAGEN’s leading position in human identification and forensics.

合作旨在创建新颖的数字PCR分析方法，以提高用于法医学和人类鉴定的人类样本DNA分析的成功结果//DNA定量使执法和法医研究人员能够更快，更准确，更可靠地分析更广泛的证据//合作加强了QIAGEN在人类鉴定和法医学方面的领先地位。

Venlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a cooperative research and development agreement (CRADA) with the U.S. Federal Bureau of Investigation (FBI) to develop a novel test for its QIAcuity digital PCR devices that will boost forensics by improving the quantification of DNA in human samples..

荷兰芬洛和华盛顿特区，2024年5月7日（环球通讯社）--QIAGEN（纽约证券交易所：QGEN；法兰克福主要标准：QIA）今天宣布与美国联邦调查局（FBI）签署合作研发协议（CRADA），为其QIAcuity数字PCR设备开发一种新的测试方法，通过改进人类样本中DNA的定量来提高法医学。。

The collaboration aims to develop a first-of-its-kind digital PCR (dPCR) assay that can simultaneously quantify in absolute terms nuclear and mitochondrial DNA concentrations, male DNA, and include quality markers for degradation and inhibition.

该合作旨在开发首创的数字PCR（dPCR）检测方法，该方法可以同时定量绝对核和线粒体DNA浓度，男性DNA，并包括降解和抑制的质量标记。

Forensic samples often contain very small amounts of DNA, which can be further compromised by age or environmental factors such as soil. Compared to traditional quantitative PCR, dPCR offers a higher tolerance to inhibitors and enables forensic specialists to detect and quantify even minimal amounts of DNA with high accuracy.

法医样本通常含有非常少量的DNA，这些DNA可能会因年龄或土壤等环境因素而进一步受损。与传统的定量PCR相比，dPCR对抑制剂具有更高的耐受性，使法医专家能够高精度地检测和定量甚至最少量的DNA。

This capability significantly improves the success rate of forensic analysis while saving time and money..

这一功能大大提高了法医分析的成功率，同时节省了时间和金钱。。

Accurate DNA quantification in casework samples is also crucial for informed workflow decisions in successful next-generation sequencing (NGS) analysis. By using the appropriate amount of DNA in library preparation, sequencing errors or biases are minimized. NGS is particularly important for analyzing mitochondrial DNA in traces without nuclear DNA, such as shed hairs, aged bones and teeth, or environmentally exposed samples.

在成功的下一代测序（NGS）分析中，案例样本中准确的DNA定量对于明智的工作流程决策也至关重要。通过在文库制备中使用适量的DNA，可以最大程度地减少测序错误或偏差。NGS对于分析没有核DNA的痕迹中的线粒体DNA特别重要，例如脱落的头发，老化的骨骼和牙齿或环境暴露的样品。

This analysis plays a critical role in identifying human remains..

这种分析在识别人类遗骸方面起着至关重要的作用。。

CRADAs enable the sharing of resources and expertise for collaborative research that advances the FBI mission. “The FBI conducts research to develop new capabilities that advance forensic science. This novel digital PCR assay could benefit the FBI and other forensic laboratories. We are excited to collaborate with QIAGEN to evaluate the potential of this capability in forensic casework,” said Eric Pokorak, Assistant Director, FBI Laboratory Division..

CRADAs能够共享资源和专业知识，促进FBI任务的合作研究。美国联邦调查局实验室部助理主任埃里克·波科拉克表示：“联邦调查局进行研究，以开发新的能力，推动法医学的发展。这种新型的数字PCR检测方法可以使联邦调查局和其他法医实验室受益。我们很高兴与QIAGEN合作，评估这种能力在法医案件工作中的潜力。”。。

“QIAGEN is proud to be working with the FBI Laboratory Division to create one of the first forensic assays able to quantify mitochondrial DNA,” said Richard Price, Vice President and head of the HID and Forensics business at QIAGEN. “Better DNA quantification will allow the FBI’s scientists and the forensic community to analyze a broader range of evidence more quickly, accurately and reliably, even from challenging samples.

QIAGEN的HID和法医业务副总裁兼负责人Richard Price表示：“QIAGEN很自豪能够与FBI实验室部门合作，创建了第一个能够量化线粒体DNA的法医检测方法之一。”。“更好的DNA定量将使FBI的科学家和法医界能够更快，更准确，更可靠地分析更广泛的证据，即使是来自具有挑战性的样本。

This advance in forensic science proves the relevance of dPCR in enhancing the reliability and impact of forensic evidence in convicting the guilty and exonerating the innocent.”.

法医学的这一进步证明了人权事务部在提高法医证据的可靠性和影响力方面的重要性，以定罪和无罪开释。”。

QIAGEN’s QIAcuity platform uses nanoplates to disperse a sample over thousands of tiny partitions and then read the reaction in each one simultaneously to quantify even the faintest genetic traces. The dPCR technology used in QIAcuity provides precise, binary results by counting the presence or absence of DNA molecules, resulting in a low error rate and high precision necessary for courtroom testimony..

QIAGEN的QIAcuity平台使用纳米板将样品分散在数千个小分区上，然后同时读取每个分区中的反应，以量化甚至最微弱的遗传痕迹。QIAcuity中使用的dPCR技术通过计算DNA分子的存在与否，提供了精确的二元结果，从而降低了错误率，提高了法庭证言所需的精度。。

The QIAcuity systems – available in one, four and eight-plate versions – integrate partitioning, thermocycling, and imaging into one workflow, cutting processing times to only two hours from six. With multiplexing capabilities of up to 5-plex, the one-plate version can process up to 384 samples in an eight-hour shift and the eight-plate version up to 1,248.

QIAcuity系统有一个、四个和八个板版本，将分区、热循环和成像集成到一个工作流程中，将处理时间从六个减少到只有两个小时。具有高达5重的多路复用功能，单板版本可以在八小时轮班中处理多达384个样品，而八板版本可以处理多达1248个样品。

At the end of 2023, more than 2,000 cumulative instrument placements had been made..

截至2023年底，累计进行了2000多笔工具配售。。

About the FBI’s Laboratory Division

关于FBI的实验室部门

The FBI conducts research and development activities as a recognized federal laboratory. This CRADA will support the FBI LD, a division within the Scientific and Technology Branch, whose mission is to collect, analyze and share timely scientific and technical information. The FBI LD’s primary locations are the FBI Academy in Quantico, VA and FBI Redstone in Huntsville, AL..

FBI作为公认的联邦实验室开展研究和开发活动。该CRADA将支持FBI LD，这是科学技术部门内的一个部门，其任务是收集、分析和及时共享科学技术信息。FBI LD的主要地点是弗吉尼亚州匡提科的FBI学院和阿拉巴马州亨茨维尔的FBI Redstone。。

About QIAGEN’s forensics and human identification portfolio

关于QIAGEN的法医学和人体识别组合

QIAGEN has a leading position in the human identification and forensics market, having pioneered the introduction of commercial DNA purification kits for forensic casework samples in the late 1990s. Today, its comprehensive portfolio includes solutions for processing sexual assault samples, identifying missing persons, age estimation and tissue identification, anthropology research and kinship testing..

QIAGEN在人类识别和法医市场上处于领先地位，在20世纪90年代末率先引入了用于法医案件样本的商业DNA纯化试剂盒。如今，它的综合产品组合包括处理性侵犯样本、识别失踪人员、年龄估计和组织识别、人类学研究和亲属关系测试的解决方案。。

QIAGEN is the only company to offer an integrated range of forensic solutions using PCR, dPCR, and NGS technologies, supporting law enforcement and forensic researchers through every step in the human identification pipeline – from sample collection to sample preparation to assay setup and quantification to STR and NGS analysis..

QIAGEN是唯一一家使用PCR、dPCR和NGS技术提供一系列综合法医解决方案的公司，通过人类识别流程的每一步（从样品采集到样品制备，到分析设置和定量，再到STR和NGS分析）为执法和法医研究人员提供支持。。

Early 2023, QIAGEN further expanded its range of downstream NGS-based forensic products with the acquisition of Verogen, a leader in the use of NGS technologies, to further drive the future of human identification and forensic investigation. In addition to its sample collection and preparation solutions, QIAGEN now provides sequencing and bioinformatics solutions as well as a genealogy database, thus offering the most complete portfolio in the human identification and forensics market..

2023年初，QIAGEN收购了NGS技术的领导者Verogen，进一步扩大了其下游基于NGS的法医产品的范围，以进一步推动人类身份识别和法医调查的未来。除了样品采集和制备解决方案外，QIAGEN现在还提供测序和生物信息学解决方案以及家谱数据库，从而在人类识别和法医市场上提供最完整的产品组合。。

Learn more: https://www.qiagen.com/applications/human-identity-and-forensics

了解更多信息：https://www.qiagen.com/applications/human-identity-and-forensics

About QIAGEN

关于QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials.

QIAGEN N.V.是一家总部位于荷兰的控股公司，是全球领先的样本到见解解决方案提供商，该解决方案使客户能够从包含生命构建模块的样本中获得有价值的分子见解。我们的样品技术从血液、组织和其他材料中分离和处理DNA、RNA和蛋白质。

Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).

分析技术使这些生物分子可见并准备进行分析。生物信息学软件和知识库解释数据以报告相关的可行见解。自动化解决方案以无缝且经济高效的工作流将这些功能结合在一起。QIAGEN在分子诊断（人类保健）和生命科学（学术界、制药研发和工业应用，主要是法医学）方面为全球50多万客户提供解决方案。

As of March 31, 2024, QIAGEN employed more than 5,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com..

截至2024年3月31日，QIAGEN在全球35多个地点雇用了5900多人。有关更多信息，请访问http://www.qiagen.com..

Forward-Looking Statement

前瞻性声明

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks.

本新闻稿中的某些声明可能被视为1933年《美国证券法》第27A节（经修订）和1934年《美国证券交易法》第21E节（经修订）所指的前瞻性声明。如果本文中包含的与QIAGEN产品有关的任何声明，包括用于应对新型冠状病毒大流行、发布和开发时间、营销和/或监管批准、财务和运营前景、增长和扩张、合作、市场、战略或运营结果的产品，包括但不限于其预期的调整后净销售额和调整后的稀释收益结果，都是前瞻性的，则此类声明基于当前的预期和假设，涉及许多不确定性和风险。

Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop n.

此类不确定性和风险包括但不限于与增长管理和国际运营相关的风险（包括货币波动的影响、监管流程和对物流的依赖）、经营成果的可变性和客户类别之间的分配、我们的产品在学术界、制药、应用测试和分子诊断领域的客户市场的商业开发；改变与客户、供应商和战略合作伙伴的关系；竞争；技术的快速或意外变化；QIAGEN产品需求波动（包括一般经济状况、客户资金水平和时间、预算和其他因素引起的波动）；我们获得产品监管批准的能力；成功将QIAGEN的产品应用于集成解决方案并生产此类产品的困难；QIAGEN识别和开发n的能力。

Source: QIAGEN N.V.

资料来源：QIAGEN N.V。

Category: Corporate

类别：公司

John Gilardi QIAGEN N.V. +49 2103 29 11711 ir@qiagen.com Domenica Martorana QIAGEN N.V. +49 2103 29 11244 ir@qiagen.com Thomas Theuringer QIAGEN N.V. +49 2103 29 11826 pr@qiagen.com Daniela Berheide QIAGEN N.V. +49 2103 29 11676 pr@qiagen.com

John Gilardi QIAGEN N.V.+49 2103 29 11711ir@qiagen.comDomenica Martorana QIAGEN N.V.+49 2103 29 11244ir@qiagen.comThomas Theuringer QIAGEN N.V.+49 2103 29 11826pr@qiagen.comDaniela Berheide QIAGEN N.V.+49 2103 29 11676pr@qiagen.com